How I treat posttransplant lymphoproliferative disorders
Top Cited Papers
- 12 November 2015
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 126 (20), 2274-2283
- https://doi.org/10.1182/blood-2015-05-615872
Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a potentially fatal disorder arising after solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Iatrogenically impaired immune surveillance and Epstein-Barr virus (EBV) primary infection/reactivation are key factors in the pathogenesis. However, current knowledge on all aspects of PTLD is limited due to its rarity, morphologic heterogeneity, and the lack of prospective trials. Furthermore, the broad spectrum of underlying immune disorders and the type of graft represent important confounding factors. Despite these limitations, several reviews have been written aimed at offering a guide for pathologists and clinicians in diagnosing and treating PTLD. Rather than providing another classical review on PTLD, this “How I Treat” article, based on 2 case reports, focuses on specific challenges, different perspectives, and novel insights regarding the pathogenesis, diagnosis, and treatment of PTLD. These challenges include the wide variety of PTLD presentation (making treatment optimization difficult), the impact of EBV on pathogenesis and clinical behavior, and the controversial treatment of Burkitt lymphoma (BL)-PTLD.This publication has 103 references indexed in Scilit:
- PI3Kδ Inhibition Augments the Efficacy of Rapamycin in Suppressing Proliferation of Epstein−Barr Virus (EBV)+ B Cell LymphomasAmerican Journal of Transplantation, 2013
- The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorderHaematologica, 2012
- Post‐transplant Burkitt lymphoma is a more aggressive and distinct form of post‐transplant lymphoproliferative disorderCancer, 2011
- Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★American Journal of Transplantation, 2011
- Hodgkin Lymphoma Post-Transplant Lymphoproliferative Disorder Following Pediatric Renal TransplantClinical Nuclear Medicine, 2010
- The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersHaematologica, 2010
- Multicenter Analysis of 80 Solid Organ Transplantation Recipients With Post-Transplantation Lymphoproliferative Disease: Outcomes and Prognostic Factors in the Modern EraJournal of Clinical Oncology, 2010
- How I treat EBV lymphoproliferationBlood, 2009
- Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative diseaseHaematologica, 2007
- Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantationCancer, 2005